Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A four-part CE activity was launched live-online in December ...

Kidney cancer, though less common, demands specialized support, particularly as patients on second- and third-line therapies require long-term holistic care. Therapies for kidney cancer have ...

COLUMBIA, S.C. (WIS) - Prostate, kidney, and bladder cancers are three commonly diagnosed urologic conditions at Lexington Medical Center. The hospital is using a variety of new technology to diagnose ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...

Aura Biosciences will present Phase 1 data on bel-sar for bladder cancer at the EAU Congress and host an investor event. Aura Biosciences, Inc. announced its participation in the 40th Annual European ...

Michigan's largest physician-owned oncology and hematology practice, announced the expansion of its specialty care offerings with the addition of urology services in Michigan. CHC welcomes two ...

Foundation and the UroTeragLATAM Foundation have signed a Memorandum of Understanding during the WFNMB congress in Cartagena, Colombia to collaborate on advancing Theranostics education through the ...

OWINGS MILL, Md., Nov. 19, 2025 /PRNewswire/ -- Chesapeake Urology Associates (CUA) announced today that Chesapeake Oncology-Hematology Associates (COHA), the premier oncology group in Maryland ...

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle ...

CG Oncology, Inc. announced that it will present a late-breaking abstract and three posters at the 40th Annual European Association of Urology (EAU) Congress in Madrid from March 21-24, 2025. The ...